HC Wainwright Has Optimistic Outlook of FATE Q2 Earnings

Fate Therapeutics, Inc. (NASDAQ:FATE) – Stock analysts at HC Wainwright upped their Q2 2026 EPS estimates for shares of Fate Therapeutics in a research note issued on Monday, June 8th. HC Wainwright analyst R. Burns now expects that the biopharmaceutical company will earn ($0.27) per share for the quarter, up from their previous forecast of ($0.29). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Fate Therapeutics’ Q3 2026 earnings at ($0.28) EPS, Q4 2026 earnings at ($0.28) EPS and FY2026 earnings at ($1.09) EPS.

A number of other research analysts have also commented on FATE. Weiss Ratings upgraded Fate Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. Jefferies Financial Group set a $4.00 price target on Fate Therapeutics in a research note on Tuesday, May 19th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $5.13.

Fate Therapeutics Price Performance

Shares of Fate Therapeutics stock opened at $1.90 on Wednesday. The firm has a 50 day simple moving average of $1.76 and a 200 day simple moving average of $1.37. Fate Therapeutics has a fifty-two week low of $0.91 and a fifty-two week high of $2.88. The firm has a market cap of $221.46 million, a P/E ratio of -1.74 and a beta of 2.53.

Fate Therapeutics (NASDAQ:FATE) last announced its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03. Fate Therapeutics had a negative net margin of 2,056.79% and a negative return on equity of 58.89%. The company had revenue of $1.30 million during the quarter, compared to the consensus estimate of $1.49 million.

Insider Transactions at Fate Therapeutics

In other Fate Therapeutics news, insider Cindy Tahl sold 25,590 shares of Fate Therapeutics stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $1.88, for a total transaction of $48,109.20. Following the completion of the sale, the insider owned 628,155 shares of the company’s stock, valued at approximately $1,180,931.40. The trade was a 3.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 4.74% of the company’s stock.

Institutional Investors Weigh In On Fate Therapeutics

A number of institutional investors have recently made changes to their positions in FATE. Comerica Bank lifted its stake in Fate Therapeutics by 55,698.6% in the first quarter. Comerica Bank now owns 82,024 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 81,877 shares during the period. AQR Capital Management LLC increased its stake in shares of Fate Therapeutics by 296.4% in the 1st quarter. AQR Capital Management LLC now owns 585,025 shares of the biopharmaceutical company’s stock valued at $462,000 after acquiring an additional 437,423 shares during the last quarter. Jane Street Group LLC increased its stake in shares of Fate Therapeutics by 106.9% in the 1st quarter. Jane Street Group LLC now owns 63,691 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 32,911 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Fate Therapeutics by 7.0% in the 2nd quarter. Geode Capital Management LLC now owns 2,429,167 shares of the biopharmaceutical company’s stock valued at $2,721,000 after acquiring an additional 159,558 shares during the period. Finally, Invesco Ltd. raised its position in shares of Fate Therapeutics by 19.6% in the 2nd quarter. Invesco Ltd. now owns 255,372 shares of the biopharmaceutical company’s stock valued at $286,000 after acquiring an additional 41,869 shares during the period. 97.54% of the stock is owned by institutional investors and hedge funds.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of first?in?class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off?the?shelf natural killer (NK) and T?cell products designed to overcome limitations of donor?derived approaches. Fate’s research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.

Central to Fate’s pipeline are multiple iPSC?derived cell therapy candidates in active clinical development.